Company profile
Cullinan Therapeutics, Inc.
NASDAQ:CGEMBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (3)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| VK-2019 | phase1_2 | — | 1 | terminated |
| ZIPALERTINIB | phase1_2 | — | 1 | active |
| Isuventatug | phase1 | — | 2 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (12)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04036682 | phase1_2 | active_not_recruiting | 2019-10-31 | 2025-10-13 | Cullinan Therapeutics Inc. | A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer |
| NCT07722767 | phase1 | not_yet_recruiting | 2026-10-15 | 2027-09-30 | Cullinan Therapeutics Inc. | A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients |
| NCT07738822 | phase1_2 | not_yet_recruiting | 2026-12-01 | 2029-01-01 | Cullinan Therapeutics Inc. | A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA |
| NCT06381141 | phase1 | active_not_recruiting | 2024-09-03 | 2026-09-01 | Cullinan Therapeutics Inc. | A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma |
| NCT05117476 | phase1 | active_not_recruiting | 2021-10-29 | 2026-03-01 | Cullinan Therapeutics Inc. | A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors |
FDA applications (0)
No records yet.